GenSight Biologics S.A.
SIGHT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €25,847 | €29,390 | €26,645 | €23,257 |
| - Cash | €270 | €2,464 | €6,940 | €2,134 |
| + Debt | €19,013 | €19,113 | €22,681 | €18,428 |
| Enterprise Value | €44,590 | €46,039 | €42,386 | €39,551 |
| Revenue | €48 | €897 | €1,728 | €1,450 |
| % Growth | -94.6% | -48.1% | 19.2% | – |
| Gross Profit | €48 | €897 | €1,728 | €1,642 |
| % Margin | 100% | 100% | 100% | 113.2% |
| EBITDA | -€6,710 | -€7,413 | -€7,342 | -€11,505 |
| % Margin | -13,979.2% | -826.4% | -424.9% | -793.4% |
| Net Income | -€6,967 | -€8,153 | -€5,848 | -€14,258 |
| % Margin | -14,514.6% | -908.9% | -338.4% | -983.3% |
| EPS Diluted | -0.054 | -0.075 | -0.071 | -0.28 |
| % Growth | 27.5% | -5.9% | 74.8% | – |
| Operating Cash Flow | -€2,459 | -€5,592 | -€7,345 | -€8,455 |
| Capital Expenditures | €0 | €1 | -€1 | -€10 |
| Free Cash Flow | -€2,459 | -€5,591 | -€7,346 | -€8,465 |